Business Standard

Less-threatening Omicron lowers Covid-19 vaccine sales estimate

Sales of Covid-19 vaccines, excluding those from China and India, will increase to about $85 billion in 2022, down about 28 per cent from an earlier estimate of $118 billion

Coronavirus vaccine, Covid-19 vaccines
Premium

Bloomberg
Evidence that omicron causes less-severe disease than earlier Covid-19 variants will likely blunt growth in vaccine sales this year as wealthier countries rein in purchases, according to Airfinity.

Sales of Covid-19 vaccines, excluding those from China and India, will increase to about $85 billion in 2022, down about 28 per cent from an earlier estimate of $118 billion, London-based Airfinity said Friday. The revision was also due to lower prices paid by poorer nations that are finally obtaining shots, the analytics firm said.

Omicron has spread rapidly but appears less likely to cause hospitalisations and deaths than predecessors such as delta, which

Don't miss the most important news and views of the day. Get them on our Telegram channel

First Published: Jan 22 2022 | 1:38 AM IST

Explore News

To read the full story, subscribe to BS Premium now, at just Rs 249/ month.

Key stories on business-standard.com are available only to BS Premium subscribers.

Register to read more on Business-Standard.com